Pharmaceuticals, Biotechnology and Life Sciences
Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.
Sareum Holdings, a drugmaker focused on cancer drugs on Monday announced cashing a $2.0 million milestone payment as part of the Chk1 licence agreement between its co-investment partner, the CRT Pioneer Fund, and Sierra Oncology, formerly known as ProNAi Therapeutics.
Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), has signed an distribution agreement…
Abivax said on Tuesday it would receive €8.4 million from “Projets de R&D Structurants Pour la Compétitivité” (PSPC) of the “Invest in the Future Program” (PIA).
Futura Medical (Futura) has signed a licensing agreement with the UK subsidiary of STADA Arzneimittel AG (STADA), for the commercialisation of TPR100, its pain relief gel.
A UK-based maker of hair and skin care products InnovaDerma has been engaged in looking for an independent non-executive Director of the company, as Garry Lemair has decided to step down the board immediately, the company said on Tuesday.
On 28 October 2016, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014…
Clinigen Group has made a deal with Cumberland Pharmaceuticals to market another product in the US, this time an oncology drug Totect (dexrazoxane hydrochloride).
An IT provider for healthcare market Instem, has appointed MaryBeth Thompson as Chief Operating Officer of the Group. Thompson has not been appointed to the company’s main Board, and she will report to Phil Reason, CEO.
Oxular Limited, a retinal therapeutics company, has promoted David Fellows, previously Non-Executive Director, as the Company’s Chairman of the Board. Fellows will replace Dr. Nigel Pitchford, who will continue on Oxular’s Board as a Director.